Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Hits Key

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
87
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Hits Key Study Milestone as Early MS Imaging Data Shows Promising Signal


Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.

- Multiple sclerosis is one of the most common neurological diseases affecting young adults worldwide.

- Study is evaluating technique that allows researchers to tell the difference between nerve damage that may still be reversible and damage that is permanent.

- Quantum BioPharma reports two key developments: patient enrollment in the pilot study has reached its halfway mark and preliminary imaging data is encouraging.

A key imaging study examining a novel approach to tracking multiple sclerosis (“MS”) has reached its halfway point in patient enrollment, with early results showing a meaningful signal in MS lesions. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on neurodegenerative and metabolic disorders, announced the milestone as part of its ongoing imaging collaboration with Massachusetts General Hospital, where researchers are evaluating a novel positron emission tomography (“PET”) imaging tracer that could support the development of Lucid-MS, the company’s MS drug candidate.

Multiple sclerosis is one of the most common neurological diseases affecting young adults worldwide. Approximately 2.9 million people are living with the disease globally, and nearly one million of those individuals are in the United States. Most people are diagnosed between the ages of 20 and 40, meaning MS strikes during some of the most productive years of a person’s life.

The disease attacks the central nervous system by damaging myelin, the protective coating around nerve fibers. This damage disrupts communication between the brain and the rest of the body. Symptoms can range from fatigue, numbness and vision problems to severe mobility impairment, cognitive difficulty and paralysis. The course of MS is unpredictable, and for many patients, the disease progresses in ways that are difficult to foresee or control.

Treatments exist that can slow the disease’s progression and reduce the frequency of relapses. But no therapy has yet demonstrated the ability to reliably halt or reverse the underlying nerve damage that drives long-term disability. That gap represents one of the central unmet needs in modern neurology. Better ways of measuring that damage, and of knowing whether a drug is actually protecting or repairing the nervous system, are urgently needed.

This is where Quantum BioPharma’s work with Massachusetts General Hospital becomes particularly significant. The study centers on a novel PET imaging technique using the tracer [¹⁸F]3F4AP, developed by Dr. Pedro Brugarolas, an investigator in radiology at MGH and assistant professor at Harvard Medical School. The technique is designed to detect demyelinated neurons that still have intact axons. That distinction matters enormously. It allows researchers to tell the difference between nerve damage that may still be reversible and damage that is permanent.

The announcement highlights two key developments. First, patient enrollment in the pilot study has reached its halfway mark. Reaching that midpoint is a meaningful operational signal. It indicates the study is progressing on schedule and moving toward the dataset size needed to draw reliable conclusions.

Second, the preliminary imaging data is encouraging. The first cohort of participants has been imaged using both advanced PET/MR and total-body PET platforms. Preliminary analyses show a robust signal in acute MS lesions, along with potential sensitivity to gray matter lesions. If those early findings hold as enrollment continues, the imaging approach could provide a more direct and quantitative way to track myelin loss and repair over time.

“We are excited to reach this important midpoint in our study with MGH and encouraged by the strength of the preliminary imaging data,” said Quantum BioPharma VP over scientific and clinical affairs Dr. Andrzej Chruscinski. “PET imaging with [¹⁸F]3F4AP has the potential to fundamentally change how we assess demyelination, providing a direct window into axonal health and enabling us to more clearly demonstrate the impact of therapies like Lucid-MS that aim to protect and restore the myelin sheath in MS.”

Brugarolas added that the ability to directly quantify demyelinated lesions with intact axons in living patients fills an important gap in MS research. “If further validated, this imaging approach could provide a more direct and quantitative measure of myelin loss and repair, which may help improve the evaluation of disease mechanisms and therapeutic response in MS,” he said.

These findings are directly relevant to Lucid-MS, the company’s investigational compound designed to inhibit demyelination by targeting the enzyme PAD2, which is implicated in myelin degradation. Lucid-MS previously completed phase 1 clinical trials with a favorable safety profile and was well tolerated in healthy participants, providing a strong foundation for the next stage of development. In March 2026, the company submitted an Investigational New Drug application to the FDA for a phase 2 trial.

A more precise imaging tool and a drug candidate designed to address the underlying cause of MS make for a compelling combination. Reaching the enrollment midpoint with promising early data suggests the science is holding up under real clinical conditions.

For more information, visit www.QuantumBioPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer

Quantum Biopharma Ltd. (QNTM) Stock Research Links

QNTM Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

IT Tech Packaging's Going-Concern Warning Lands Hard

Updated Category News Views 55

A paper maker can survive plenty of ugly quarters; it cannot casually shrug off an auditor questioning whether it can keep operating. That is the cold part of IT Tech Packaging's Nov. 19 disclosure. Its newly filed Form 10-K for the year ended Dec. 31, 2025 carries a “Material Uncertainty Related to Going Concern” paragraph from Audit Alliance LLP. Nobody should dress...

Continue Reading
MemorialCare Adds AI Guardrails for Hidden Aneurysms

Updated Category News Views 73

A brain scan ordered for one reason can suddenly expose a risk nobody knew was sitting there. That is the sober promise behind MemorialCare Neuroscience Institute's rollout of Rapid Aneurysm, an artificial-intelligence tool embedded in qualifying CTA and MRA brain scans across its inpatient and outpatient network. MemorialCare says it is the first health system in Los...

Continue Reading
ATRenew's Q3 Profit Jump Meets a Cash Balance Test

Updated Category News Views 105

Used phones do not make for glamorous investing, but this quarter has some real muscle behind it. ATRenew turned a 25.3% revenue gain into a 57.9% jump in operating income for the three months ended September 30, and that is the sort of operating leverage I want to see before getting carried away with a circular-economy story. Margins Finally Move in the Right Direction...

Continue Reading
First Horizon Opens Its Charlotte Office in South End

Updated Category News Views 79

A Building Is Not a Balance Sheet Charlotte got a fresh First Horizon sign at 110 East Boulevard on Nov. 19, 2026, and that is a sensible move, not a magic trick. The bank has officially opened a corporate office in the city’s South End neighborhood, positioning the team to develop client relationships across the Charlotte area and broaden its regional footprint. That...

Continue Reading
PepsiCo Locks In Hyatt's 700-Property U.S. Supply Deal

Updated Category News Views 76

A hotel minibar is a lousy place to hunt for glamour, but it is a terrific place to spot durable distribution. PepsiCo has renewed its U.S. food and beverage relationship with Hyatt for 10 years, covering more than 700 properties. Nobody should pretend a hotel contract transforms a company with nearly $94 billion in 2025 revenue. Still, this is the sort of unflashy...

Continue Reading
PostalAnnex Adds Roseville Store as Owners Reach Three

Updated Category News Views 97

A third storefront from the same operators says more than a ribbon-cutting ever will. Aarondeep Hira and Manraj Sangha have opened a PostalAnnex in Roseville, California, their third Sacramento-area location after earlier operations in Sacramento and Antelope. For a franchise system, repeat ownership is the part worth noticing. It is not a guarantee of booming sales, and...

Continue Reading
Genome-Written XDP Mice Could Sharpen Drug Research

Updated Category News Views 60

Seventy-eight thousand DNA letters changed the pace of a cruel little-known disease story. NYU Langone researchers inserted a human disease-linked stretch of genetic material into mice and produced an accelerated model of X-linked dystonia-parkinsonism, or XDP. That is a serious laboratory accomplishment, not a cure announcement, and it deserves to be read with both...

Continue Reading
Makers Nutrition Backs Families Through Friends of Karen

Updated Category News Views 60

A thousand dollars in gift cards can look modest beside the noise of holiday marketing, but it lands differently when a family is carrying the weight of a child’s life-threatening illness. Makers Nutrition, a Hauppauge, New York-based private-label and custom supplement manufacturer, has donated $1,000 in gift cards to Friends of Karen for the nonprofit’s annual...

Continue Reading
Dario's WebMD Deal Opens a Vast, Unproven Channel Path

Updated Category News Views 122

One partnership can look like a gold mine from across the valley; getting the ore out is another matter entirely. DarioHealth has struck a strategic partnership with WebMD Health Services that could put its multi-condition care platform in front of an enormous commercial ecosystem: more than 3,500 employers and 65 million covered lives. That is a meaningful distribution...

Continue Reading
JDEnergy's RE+ Push Meets a Grid Hungry for Storage

Updated Category News Views 64

Certification Is Useful, Not a Victory Lap A battery box earning a safety certificate is not usually thrilling stuff, but the timing matters here. On Nov. 19, 2026, JDEnergy laid out its North American storage pitch at RE+ in Las Vegas while electricity demand is getting shoved higher by industrial buildout and AI data centers. Add more variable renewable generation to an...

Continue Reading

Top 5 Most Recently Viewed Articles

Immutable Expands Web3 Gaming Influence in Major Conference

Updated Category News Views 257

Immutable's Growing Presence at GDC 2025 Immutable is affirmatively stepping into the spotlight at the upcoming Game Developers Conference (GDC) 2025, a pivotal event that congregates the brightest minds of the gaming industry. With collaborations alongside notable partners such as RavenQuest, Polygon Labs, Sequence, and MetaGravity, Immutable is ready to showcase its...

Continue Reading
Rathbones Group's Influence on Empiric Student Property Plc

Updated Category News Views 239

Understanding Public Opening Position Disclosures Public opening position disclosures are essential for maintaining transparency in financial markets. This process is especially important for stakeholders interested in relevant securities, particularly when holdings exceed 1%. Disclosures must provide critical information on who owns shares and any short positions related...

Continue Reading
Rapid Nexus Achieves Historic Milestone in Wound Care Technology

Updated Category News Views 389

Rapid Nexus Receives FDA Clearance for Hemastyl Gel The FDA 510(k) clearance for its Hemastyl gel device marks the first technology that has treated the tissue surrounding chronic wounds and prevented numerous amputations. On a significant day in the realm of wound care, Rapid Nexus, a pioneering California-based med-tech company, has announced the receipt of FDA 510(k)...

Continue Reading
Grainger Approves Substantial Dividend to Shareholders

Updated Category News Views 131

Grainger's Commitment to Shareholders Through Dividends W.W. Grainger, Inc. (NYSE: GWW) has recently taken significant steps to reward its investors. The board of directors has officially approved a cash dividend of $2.26 per share. This strong move by Grainger underscores its commitment to providing long-term value to its shareholders. Details of the Dividend...

Continue Reading
Grupo Aeroportuario del Pacífico Secures New Credit Line Deal

Updated Category News Views 236

Grupo Aeroportuario del Pacífico Unveils Expanded Credit Line Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (PAC), a prominent player in the Mexican aviation sector, has recently announced a significant refinancing of its credit arrangements. The company has successfully secured a USD $40 million credit line from Banco Nacional de México, S.A. (Banamex). This...

Continue Reading